UK markets closed
NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.76 +0.28 (+0.36%) GOLD FUTURES
2,322.30 -8.90 (-0.38%) DOW
38,909.95 +57.68 (+0.15%) Bitcoin GBP
50,857.94 +191.83 (+0.38%)
Fusion Pharmaceuticals Inc. (FUSN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 12:25PM EDT. Market open.
| Previous close | 21.42 |
| Open | 21.44 |
| Bid | 21.43 x 100 |
| Ask | 21.44 x 100 |
| Day's range | 21.39 - 21.47 |
| 52-week range | 2.31 - 21.58 |
| Volume | |
| Avg. volume | 2,072,590 |
| Market cap | 1.82B |
| Beta (5Y monthly) | -0.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.45 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.38 |
PR NewswireFusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today reported financial results for the first quarter ended March 31, 2024, and provided an update on clinical and corporate developments.
ZacksFusion Pharmaceuticals Inc. (FUSN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Fusion Pharmaceuticals (FUSN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksFusion (FUSN) to Report Q1 Earnings: Here's What to Expect
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
© 2024 Yahoo. All rights reserved.